when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

by stage

Marketed
Phase 3
Phase 2
Phase 1
Preclinical

browse

Most catalysts
Recently active
All drugs →
Companies
Patent cliff

what

Trial readouts
PDUFA dates
Approvals
Earnings

when

Upcoming
Month grid
Recently passed

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News
Drugs
Calendar
Companies

Hubs

Topics
Patent cliff
Publications
Readouts

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

JOURNEY · news · pharmadog

← back to JOURNEY

News mentioning JOURNEY

113 stories

Sep 8, 26Can Benelux turn scientific strength into larger biotech scale?biospace

Sep 8, 26Reeling from past failures, Parkinson's pipeline enters 'era of diversification'biospace

Sep 8, 26Inhibrx CEO says progression-free survival data leave ‘no question’ about OX40 agonist’s durabilityfiercebiotech

Sep 7, 26Guardant wins FDA nod for diagnostic guiding use of AstraZeneca’s Etcamahfiercebiotech

Sep 4, 26Opinion: The FDA removed the red tape around one of the best drugs for children with schizophrenia. But the fear remainsstat

Sep 1, 26Is Moderna, Merck's mRNA cancer vaccine win the start of a 'personalized medicine revolution'?fiercebiotech

Aug 26, 26RevMed receives early FDA approval for ‘groundbreaking’ pancreatic cancer drugbiospace

Aug 26, 26Biohaven trades cash for ‘upside’ with $795M epilepsy drug dealbiopharma dive

Aug 25, 26After some ‘tough years,’ Frontier’s CEO is ramping up ambitions for precision med platformfiercebiotech

Aug 25, 26Founded by Metsera backers, Sentivera emerges with $1.5B inflammatory disease dealfiercebiotech

Aug 24, 26Safety concerns spur FDA to again halt testing of Regenxbio gene therapybiopharma dive

Aug 19, 26She grew up unvaccinated. Now she’s a leading voice for science — and empathystat

Aug 14, 26‘We’re not afraid of competition’: BioCryst CEO sets out strategy after scrapping internal discoveryfiercebiotech

Aug 10, 26Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipelinebiospace

Aug 10, 26Regulatory operations: The overlooked half of submission readinessbiopharma dive

Aug 7, 26Novo Nordisk’s CFO on the oral Wegovy rollout and beyondfiercebiotech

Aug 6, 26Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800Mbiopharma dive

Aug 6, 26With $263M, LifeMine unearths a new drug for organ transplantsbiopharma dive

Aug 6, 26CROs vs. biotechs: Finding the right fitbiospace

Aug 5, 26‘It’s been a roller coaster’: Novo Nordisk’s CFO reflects on ‘pressure’ to drive growthfiercebiotech

Aug 4, 26Sanofi-backed Expedition uses $115M series B to advance COPD drug on phase 2 journeyfiercebiotech

Aug 4, 26Opinion: How Josée became one of the 7.9% of Québécois who die by assisted suicidestat

Aug 3, 26BlossomHill eyes $112M IPO harvest to bankroll potential Tagrisso challengerfiercebiotech

Jul 30, 26Daiichi’s pipeline falls behind rivals as cash flow nears peak: analystsbiospace

Jul 29, 26Vertex’s latest autoimmune TCE play involves $28M upfront to AbCellerafiercebiotech

Jul 28, 26Eli Lilly tops new biopharma ranking on launch success, development speedfiercebiotech

Jul 27, 26STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and morestat

Jul 27, 26[Podcast] From Protocol to Patient: Inside Clinical Supply with Almac Clinical Servicesbiopharma dive

Jul 27, 26FDA has recommitted to adcomms—but to what end?biospace

Jul 24, 26Scribe secures $129M in a rare gene editing IPObiopharma dive

← prevpage 3 of 4next →